Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1838]
News [4199]
Articles [376]
Editorials [10]
Conferences [105]
elearning [29]
New era of early cancer detection blood tests on the horizon
Dr Deborah Schrag - Memorial Sloan Kettering Cancer Center, New York City, USA
New era of early cancer detection blood tests on the horizon ( Dr Deborah Schrag - Memorial Sloan Kettering Cancer Center, New York City, USA )
11 Sep 2022
Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC...
Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San...
Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and QoL update ( Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )
11 Sep 2022
HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan
Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston...
HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan ( Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston, USA )
11 Sep 2022
Lasofoxifene shows promise for women with ESR1-mutated mBC
Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San...
Lasofoxifene shows promise for women with ESR1-mutated mBC ( Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )
11 Sep 2022
Extended adjuvant AI not advised for HPBC after 5+ yrs of sequential endocrine...
Dr Vivianne Tjan-Heijnen - Maastricht University Medical Center, Maastricht...
Extended adjuvant AI not advised for HPBC after 5+ yrs of sequential endocrine therapy ( Dr Vivianne Tjan-Heijnen - Maastricht University Medical Center, Maastricht, Netherlands )
11 Sep 2022
Prognostic model of all-cause mortality at 30 days in patients with cancer and...
Dr Chris Labaki - Dana-Farber Cancer Institute, Boston, USA
Prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19 ( Dr Chris Labaki - Dana-Farber Cancer Institute, Boston, USA )
11 Sep 2022
Metastatic breast cancer endpoints for survival: rwPFS and TTNT
Dr Chris Labaki - Dana-Farber Cancer Institute, Boston, USA
Metastatic breast cancer endpoints for survival: rwPFS and TTNT ( Dr Chris Labaki - Dana-Farber Cancer Institute, Boston, USA )
10 Sep 2022
New data presented at ESMO for multi-cancer early detection
Dr Tom Beer - Vice President and Chief Medical Officer of Exact Sciences
New data presented at ESMO for multi-cancer early detection ( Dr Tom Beer - Vice President and Chief Medical Officer of Exact Sciences )
10 Sep 2022
Olaparib continues to show positive results in advanced ovarian cancer - 7 year...
Prof Paul DiSilvestro - Women & Infants Hospital, Providence, USA
Olaparib continues to show positive results in advanced ovarian cancer - 7 year data ( Prof Paul DiSilvestro - Women & Infants Hospital, Providence, USA )
10 Sep 2022
OncoAlert and ecancer weekly round up for August 15th - 21st, 2022
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly round up for August 15th - 21st, 2022 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
22 Aug 2022
Working to improve global cancer care access in low middle-income countries
Dr Julie Gralow, Prof Eduardo Cazap
Working to improve global cancer care access in low middle-income countries ( Dr Julie Gralow, Prof Eduardo Cazap )
25 Jul 2022
Palbociclib shows improved PFS but not improved OS for ER+ HER2- mBC patients
Dr Bishal Gyawali - Queen's University, Kingston, Canada
Palbociclib shows improved PFS but not improved OS for ER+ HER2- mBC patients ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
19 Jul 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation